Tarsus Pharmaceuticals, Inc.
TARS
Classement en actions
#4544
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Prix de l'action
$70.61
Capitalisation boursière
$3.30B
Changement (1 jour)
0.16%
Changement (1 an)
2.78%
Pays
US
Échange Tarsus Pharmaceuticals, Inc. (TARS)
Catégorie
Healthcare
Historique du prix de l'action pour Tarsus Pharmaceuticals, Inc. (TARS)
Prix de clôture le plus élevé : $72.19 le 2026-10-01
Prix de clôture le plus bas : $21.51 le 2020-10-01
Prix de clôture le plus bas : $21.51 le 2020-10-01
Historique du prix de l'action de Tarsus Pharmaceuticals, Inc. de 2020 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $536.91 | 25.90% |
US
|
|
| $230.20 | 757.36% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $892.44 | 9.61% |
NL
|
|
| $291.76 | 2.51% |
BE
|
